유방암 검진 및 진단 시장 - 세계 및 지역 분석 : 제품, 용도, 최종사용자, 지역, 국가별 - 분석과 예측(2026-2036년)

This report can be delivered within 1 working day.

Introduction of the Breast Cancer Screening and Diagnostics Market

The global breast cancer screening and diagnostics market, initially valued at $5,503.4 million in 2025, is projected to witness substantial growth, reaching $12,152.0 million by 2036, marking a remarkable compound annual growth rate (CAGR) of 7.49% over the period from 2026 to 2036.

The global breast cancer screening and diagnostics market has been witnessing significant growth, driven by the increasing incidence of breast cancer, rising awareness regarding the importance of early detection, and continuous advancements in diagnostic technologies. Breast cancer remains the most commonly diagnosed cancer among women worldwide. According to the World Health Organization (WHO), approximately 2.3 million women were diagnosed with breast cancer in 2022, and the disease accounted for nearly 670,000 deaths globally, highlighting the urgent need for effective screening and timely diagnosis. Breast cancer screening encompasses a range of imaging and laboratory-based techniques, including mammography, breast ultrasound, magnetic resonance imaging (MRI), molecular breast imaging, tomosynthesis (3D mammography), and emerging artificial intelligence (AI)-assisted diagnostic platforms. These technologies play a critical role in detecting malignancies at earlier stages, enabling timely intervention, improving survival outcomes, and reducing treatment costs.

Rapid technological innovation is transforming the landscape of breast cancer screening and diagnostics by enhancing diagnostic accuracy, improving workflow efficiency, and enabling personalized patient management. The widespread adoption of digital mammography and digital breast tomosynthesis has significantly improved lesion detection, particularly among women with dense breast tissue, while AI-powered image analysis is helping radiologists identify suspicious findings with greater confidence and consistency. Liquid biopsy technologies, genomic profiling, and advanced biomarker testing are also expanding the role of precision diagnostics in breast cancer management. Furthermore, governments and healthcare organizations across developed and emerging economies continue to strengthen national screening initiatives. For instance, the European Commission's updated Breast Cancer Screening Initiative encourages organized screening programs across member states, while countries such as the United States, the United Kingdom, Canada, Australia, and Japan continue to expand population-based screening coverage. Although challenges such as high equipment costs, disparities in healthcare access, and false-positive diagnostic outcomes remain, ongoing technological advancements, increasing healthcare investments, and the growing emphasis on preventive oncology are expected to sustain long-term growth in the global breast cancer screening and diagnostics market.

Market Introduction

The global breast cancer screening and diagnostics market is experiencing robust expansion as healthcare systems worldwide increasingly prioritize early cancer detection to reduce disease burden and improve patient survival. Screening technologies such as digital mammography, breast ultrasound, breast MRI, contrast-enhanced mammography, molecular imaging, and digital breast tomosynthesis have become integral components of breast cancer detection programs, while advanced diagnostic solutions, including immunohistochemistry, molecular diagnostics, genomic assays, and biopsy technologies, are supporting accurate disease characterization and treatment planning. According to the International Agency for Research on Cancer (IARC), breast cancer accounts for approximately one in every four cancers diagnosed among women globally, reinforcing the growing demand for accessible and reliable screening infrastructure. Increasing public awareness campaigns, favorable reimbursement policies in developed economies, and expanding screening initiatives in emerging markets are further accelerating the adoption of advanced diagnostic technologies.

Continuous innovation in imaging systems, molecular diagnostics, and artificial intelligence is reshaping the competitive landscape of the breast cancer screening and diagnostics market. AI-enabled computer-aided detection (CAD) systems are enhancing radiologists' diagnostic performance by improving image interpretation accuracy and reducing reading times, while next-generation sequencing (NGS), gene expression profiling, and companion diagnostics are supporting precision oncology and individualized treatment strategies. Major industry participants are also introducing portable imaging solutions, cloud-connected diagnostic platforms, and AI-integrated workflow management systems to improve accessibility and operational efficiency across hospitals, diagnostic imaging centers, and specialized breast care clinics. Additionally, increasing investments in women's health, expansion of mobile mammography programs, and growing collaborations between healthcare providers, research institutions, and technology developers are strengthening market growth globally. While regulatory approval processes, affordability challenges in low- and middle-income countries, and workforce shortages may influence adoption rates in certain regions, the continued emphasis on early diagnosis, technological advancement, and precision medicine is expected to drive sustained growth in the global breast cancer screening and diagnostics market over the coming years.

Industrial Impact

The global breast cancer screening and diagnostics market is creating a substantial impact on the healthcare and diagnostic imaging industry by advancing early cancer detection, improving diagnostic precision, and supporting personalized oncology care. Leading industry participants such as Hologic, Inc., GE HealthCare, Siemens Healthineers, Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Canon Medical Systems Corporation, Roche Diagnostics, QIAGEN N.V., Becton, Dickinson and Company (BD), and Illumina, Inc. are continuously investing in innovative imaging systems, molecular diagnostics, biopsy technologies, and artificial intelligence (AI)-enabled solutions to improve breast cancer detection and clinical decision-making. The introduction of digital breast tomosynthesis (3D mammography), contrast-enhanced mammography, automated breast ultrasound systems (ABUS), breast MRI, AI-assisted image interpretation, and genomic testing is significantly improving the detection of early-stage tumors, particularly among women with dense breast tissue and those at elevated genetic risk. These technological advancements are enabling healthcare providers to reduce false-positive and false-negative findings, enhance diagnostic confidence, and optimize treatment planning across diverse patient populations.

From an industry perspective, the evolution of breast cancer screening and diagnostics is accelerating the transition toward integrated, data-driven, and patient-centered breast care ecosystems. Hospitals, dedicated breast imaging centers, and diagnostic laboratories are increasingly adopting comprehensive diagnostic platforms that combine advanced imaging modalities with pathology, molecular diagnostics, genetic testing, and digital health technologies to streamline clinical workflows and improve multidisciplinary care. The integration of AI-powered computer-aided detection (CAD), cloud-based image management systems, radiology information systems (RIS), picture archiving and communication systems (PACS), and predictive analytics is enhancing workflow efficiency, facilitating remote interpretation, and supporting population-scale screening programs. Furthermore, increasing collaborations between medical device manufacturers, biotechnology companies, healthcare providers, and research organizations are accelerating the development of precision diagnostics and companion diagnostic solutions that support targeted therapies. By improving early detection rates, enabling risk-stratified screening strategies, reducing healthcare costs associated with late-stage disease, and strengthening preventive oncology initiatives, the breast cancer screening and diagnostics market is playing a pivotal role in transforming women's healthcare and the global cancer diagnostics industry.

Market Segmentation:

Segmentation 1: By Product

• Imaging Systems
• Diagnostic Systems
• Biopsy and Guidance Systems

Imaging Systems Segment to Dominate the Breast Cancer Screening and Diagnostics Market (by Product)

In 2025, imaging systems dominated the global breast cancer screening and diagnostics market as they represent the first-line technology for routine breast cancer detection and are the foundation of national screening programs worldwide. Mammography, particularly digital mammography and digital breast tomosynthesis (3D mammography), is widely recommended by major healthcare organizations for early detection, driving high procedure volumes and equipment demand. The growing adoption of advanced imaging modalities such as breast ultrasound, MRI, and contrast-enhanced mammography further strengthens this segment. Continuous technological advancements, including AI-assisted image analysis, enhanced image quality, and dose optimization, have improved diagnostic accuracy and workflow efficiency. Additionally, increasing government investments in organized screening programs, favorable reimbursement policies in developed countries, and the expansion of diagnostic imaging infrastructure in emerging economies continue to support the segment's market leadership. High utilization rates and recurring equipment upgrades further contribute to the dominance of imaging systems in the market.

Segmentation 2: By Application

• Screening
• Diagnosis
• Staging
• Treatment Selection
• Prognosis and Recurrence Risk Assessment
• Therapy Monitoring
• Post-Treatment Surveillance

Screening Application Segment to Dominate the Breast Cancer Screening and Diagnostics Market (by Application)

In terms of application, the screening application dominated the global breast cancer screening and diagnostics market in 2025 because early detection remains the most effective strategy for reducing breast cancer mortality and improving treatment outcomes. National and regional screening programs across countries such as the U.S., Canada, the U.K., and several European nations have significantly increased the volume of routine mammography examinations. Screening is recommended for millions of asymptomatic women, resulting in substantially higher procedure volumes than diagnostic or treatment-related applications. The widespread availability of digital mammography and 3D breast tomosynthesis, coupled with increasing public awareness and favorable reimbursement policies, has further accelerated adoption. Additionally, growing government initiatives promoting early cancer detection and expanding screening coverage in emerging economies continue to strengthen the dominance of the screening segment in the global market.

Segmentation 3: By End User

• Hospitals
• Diagnostic Imaging Centers
• Other End User

Hospitals Segment to Dominate the Breast Cancer Screening and Diagnostics Market (by End User)

In 2025, hospitals dominated the global breast cancer screening and diagnostics market as they provide comprehensive breast cancer care, integrating screening, diagnostic imaging, biopsy, pathology, molecular testing, and treatment planning within a single healthcare setting. They are equipped with advanced technologies such as digital mammography, breast MRI, ultrasound, and biopsy systems, enabling accurate diagnosis and multidisciplinary patient management. Hospitals also handle a high volume of breast cancer screening and diagnostic procedures due to strong patient inflow, established oncology departments, and access to specialized radiologists and pathologists. Furthermore, increasing investments in hospital infrastructure, favorable reimbursement policies, and the expansion of cancer care services continue to strengthen the dominance of hospitals as the leading end-user segment.

Segmentation 4: By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific
• Rest-of-the-World

North America to Dominate the Breast Cancer Screening and Diagnostics Market (by Region)

North America dominates the global breast cancer screening and diagnostics market due to its high breast cancer incidence, well-established screening programs, advanced healthcare infrastructure, and rapid adoption of innovative diagnostic technologies. The region has widespread access to digital mammography, 3D breast tomosynthesis, breast MRI, molecular diagnostics, and AI-assisted imaging, supported by favorable reimbursement policies and high healthcare expenditure. For example, the United States has one of the world's largest organized breast cancer screening populations, with organizations such as the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) recommending routine mammography for eligible women. Additionally, the presence of leading market players such as Hologic, GE HealthCare, Becton, Dickinson and Company (BD), and Danaher Corporation drives continuous product innovation and commercialization. Canada also supports market growth through organized provincial breast screening programs, further reinforcing North America's leadership in the global market.

Recent Developments in the Breast Cancer Screening and Diagnostics Market

• In March 2025, GE HealthCare launched Invenia ABUS Premium, an AI-enabled automated breast ultrasound system designed to improve supplemental screening for women with dense breast tissue through enhanced image quality and workflow automation.
• In May 2025, Hologic's Genius AI Detection PRO mammography solution received the MedTech Breakthrough Award for improving breast cancer detection accuracy and supporting radiologists with AI-assisted image interpretation.
• In October 2024, Siemens Healthineers expanded its MAMMOMAT B.brilliant mammography platform with AI-enabled workflow enhancements and advanced breast imaging capabilities designed to improve screening efficiency and patient comfort.
• In April 2024, QIAGEN expanded its oncology companion diagnostics portfolio with advanced biomarker testing solutions supporting precision medicine and treatment selection for breast cancer patients.

Demand - Drivers, Challenges, and Opportunities

Market Drivers:

Increasing Prevalence of Breast Cancer: The rising prevalence of breast cancer has been one of the strongest drivers of the global breast cancer imaging and diagnostics market. Breast cancer remains the most common cancer among women globally, creating sustained demand for screening mammography, digital breast tomosynthesis, breast ultrasound, breast MRI, image-guided biopsy, pathology testing, immunohistochemistry, and molecular diagnostics. According to the World Health Organization, around 2.3 million women were diagnosed with breast cancer globally in 2022, and approximately 670,000 deaths were reported. The disease occurs in every country and is strongly associated with age, with incidence increasing in later life. As the number of diagnosed cases continues to grow, healthcare systems are increasing investment in early detection infrastructure, diagnostic imaging capacity, biopsy workflows, and biomarker-based testing.

The market impact remains widespread because breast cancer detection typically follows a multi-stage diagnostic pathway. A screening mammogram that identifies a suspicious lesion may lead to diagnostic mammography, tomosynthesis, ultrasound, contrast-enhanced mammography, MRI, image-guided biopsy, histopathology, hormone receptor testing, HER2 testing, and genomic risk assessment in selected patients. Therefore, rising breast cancer incidence not only increases demand for first-line screening systems but also expands utilization across the broader imaging and diagnostics ecosystem. This supports growth for mammography vendors, ultrasound and MRI suppliers, biopsy device manufacturers, pathology laboratories, digital pathology platforms, AI software providers, and molecular diagnostic companies.

In the U.S., the American Cancer Society estimates that about 321,910 new cases of invasive breast cancer will be diagnosed in women in 2026, along with about 60,730 cases of ductal carcinoma in situ and about 42,140 deaths. Breast cancer accounts for about 30% of all new female cancers annually in the U.S., while incidence rates have increased by about 1% per year in recent years and by around 1.4% per year among women younger than 50. This trend is increasing demand for earlier screening, higher-capacity mammography services, diagnostic follow-up, and advanced modalities such as digital breast tomosynthesis and breast MRI in selected risk groups.

Market Challenges:

High Capital Investment and Infrastructure Requirements: High capital investment and complex infrastructure requirements continue to restrain the growth of the global breast cancer screening and diagnostics market, particularly in developing and resource-limited healthcare systems. Advanced screening and diagnostic technologies, including digital breast tomosynthesis (DBT), breast MRI, contrast-enhanced mammography, automated breast ultrasound (ABUS), image-guided biopsy systems, digital pathology platforms, and AI-enabled diagnostic software, require substantial upfront investments in equipment, facility modernization, IT integration, maintenance, and workforce training. Industry estimates indicate that digital mammography systems typically cost between $50,000 and $265,000, while advanced DBT systems can exceed $250,000, excluding installation, service agreements, software upgrades, and operating expenses.

The impact of these financial and infrastructure challenges is particularly evident in low- and middle-income countries. According to the World Health Organization (WHO), implementing population-wide mammography screening programs remains difficult in many regions due to limited healthcare infrastructure, shortages of trained radiologists and pathologists, inadequate referral systems, and constrained healthcare budgets. As a result, many healthcare providers continue to depend on clinical breast examinations, ultrasound-based diagnostics, mobile mammography services, and centralized image interpretation rather than investing in comprehensive breast imaging infrastructure. Although advanced breast imaging technologies significantly improve early detection and diagnostic accuracy, their high acquisition, maintenance, and operational costs continue to limit adoption, thereby restraining the overall growth of the global breast cancer screening and diagnostics market.

Market Opportunities:

Expanding Screening Coverage and Improving Follow-Up Compliance: Uneven access to breast cancer screening and low follow-up compliance present a significant opportunity for expansion in the global breast cancer screening and diagnostics market. In many regions, particularly underserved and lower-income populations, participation in screening programs remains limited due to affordability concerns, lack of awareness, travel distance to imaging centers, appointment delays, cultural hesitation, fear of diagnosis, and fragmented referral systems. These gaps result in a substantial portion of eligible women remaining outside routine screening pathways, thereby restricting early detection rates and downstream utilization of diagnostic imaging, biopsy, pathology, and molecular testing services.

Real-world evidence highlights this opportunity. In the U.K., NHS breast screening uptake declined from 71.1% in 2018-19 to 64.6% in 2022-23, with first-time invitee participation at just 53.7%. Despite the program detecting nearly 19,000 breast cancer cases annually and contributing to an estimated 1,300 lives saved each year, participation gaps indicate significant unmet screening potential. In response, NHS England introduced targeted interventions such as a national awareness campaign in 2025 and digital appointment systems through the NHS App to improve attendance and engagement. These initiatives demonstrate that even mature healthcare systems have considerable room to expand screening penetration and diagnostic utilization through improved patient outreach and digital engagement.

Additionally, operational gaps in screening infrastructure further reinforce this opportunity. In 2025, NHS England reported a system failure where over 5,000 individuals were not invited for routine screening due to incomplete data transfer from general practitioner records. Such incidents across screening programs highlight the need for stronger digital registries, automated invitation systems, recall management tools, and integrated healthcare IT platforms to ensure consistent patient participation and follow-up adherence.

How can this report add value to an organization?

Product/Innovation Strategy: Product and innovation strategies in the breast cancer screening and diagnostics market are focused on improving early detection accuracy and workflow efficiency. Manufacturers are advancing technologies such as digital breast tomosynthesis, high-resolution mammography, breast MRI, and automated breast ultrasound to enhance lesion detection, especially in dense breast tissue. A major shift toward AI-enabled imaging is enabling automated detection, risk assessment, and decision support, reducing diagnostic variability. Companies are also developing integrated platforms combining imaging, pathology, and molecular diagnostics for comprehensive cancer evaluation. Portable and mobile screening solutions are expanding access in underserved regions. Additionally, innovations emphasize lower radiation dose, faster scan times, and improved patient comfort, supported by cloud-based and subscription-driven software models.

Growth / Marketing Strategy: Strategic collaborations, public health partnerships, and geographic expansion are key growth drivers in the breast cancer screening and diagnostics market. Companies are increasingly targeting hospitals, diagnostic imaging centers, breast care clinics, and government-led screening programs, particularly in emerging economies where screening penetration remains low but demand is rising. The adoption of mobile mammography units, cloud-based diagnostic platforms, and AI-enabled screening workflows is expanding access in underserved regions. Manufacturers are also focusing on bundled service models, including software subscriptions, maintenance contracts, training programs, and managed screening solutions, to improve affordability and long-term customer engagement. Partnerships with healthcare providers and government agencies are further accelerating the deployment of organized screening programs and expanding market reach.

Competitive Strategy: The breast cancer screening and diagnostics market is highly competitive, with leading players such as Hologic, GE HealthCare, Siemens Healthineers, Philips, Fujifilm, Roche, and Illumina focusing on technological innovation and portfolio expansion. Competition is driven by advancements in digital mammography, DBT systems, AI-powered imaging software, molecular diagnostics, and digital pathology platforms that enhance diagnostic accuracy and workflow efficiency. Vendors are increasingly prioritizing interoperability, automation, and AI integration to improve clinical decision-making and reduce radiologist workload. The ability to deliver high-precision, low-radiation, and workflow-efficient diagnostic solutions that support early cancer detection and personalized treatment planning remains a key differentiator in the global market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for the global market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
• The scope of the report is based on comprehensive inputs from industry experts across various sectors, including hospitals, diagnostic laboratories, imaging centers, reference laboratories, and research institutions.
• The market contribution of breast cancer screening and diagnostic systems is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
• Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
• The market has been mapped based on the existing breast cancer screening and diagnostics system.
• Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts and key stakeholders across the healthcare and radiography ecosystem, including breast cancer screening and diagnostics system manufacturers (OEMs), medical device companies, radiology service providers, and healthcare institutions. Stakeholders such as hospitals, imaging centers, and screening programs have been consulted to validate adoption trends, system-level integration, and clinical utility specific to breast cancer screening and diagnostics equipments. Respondents, including CEOs, vice presidents, product and marketing directors, and technology and innovation leaders, have been interviewed to obtain and verify both qualitative and quantitative insights for this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors' presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Becton, Dickinson and Company
• Canon Inc.
• FUJIFILM Corporation
• GE Healthcare
• Koninklijke Philips N.V.
• Hologic Inc
• F. Hoffmann-La Roche Ltd
• Seno Medical
• Planmed Oy
• QIAGEN

Table of Contents

Executive Summary

Scope and Definition

1 Global Breast Cancer Screening and Diagnostics Market: Industry Outlook

• 1.1 Market Trends
  • 1.1.1 Impact Analysis
  • 1.1.2 Integration of Artificial Intelligence
• 1.2 Regulatory Landscape
  • 1.2.1 U.S.
  • 1.2.2 Europe
  • 1.2.3 Asia-Pacific
    • 1.2.3.1 China
    • 1.2.3.2 Japan
    • 1.2.3.3 India
• 1.3 Market Dynamics
  • 1.3.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • 1.3.2 Market Drivers
    • 1.3.2.1 Increasing Prevalence of Breast Cancer
    • 1.3.2.2 Expansion of Organized Screening Programs and Lower Screening Age Thresholds
    • 1.3.2.3 Adoption of Digital Breast Tomosynthesis and Advanced Mammography Technologies
  • 1.3.3 Market Challenges
    • 1.3.3.1 High Capital Investment and Infrastructure Requirements
    • 1.3.3.2 Uneven Screening Access and Low Follow-Up Compliance
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Shift from Age-Based to Risk-Stratified, Personalized Screening

2 Product

• 2.1 Imaging System
• 2.2 Diagnostics System
• 2.3 Biopsy and Guidance Systems

3 Application

• 3.1 Screening
• 3.2 Diagnosis
• 3.3 Staging
• 3.4 Treatment Selection
• 3.5 Prognosis and Recurrence Risk Assessment
• 3.6 Therapy Monitoring
• 3.7 Post-Treatment Surveillance

4 End User

• 4.1 Hospitals
• 4.2 Diagnostic Imaging Centers
• 4.3 Other End Users

5 Region

• 5.1 Regional Summary
• 5.2 North America
  • 5.2.1 Regional Overview
  • 5.2.2 Driving Factors for Market Growth
  • 5.2.3 Factors Challenging the Market
  • 5.2.4 Market Sizing and Forecast
    • 5.2.4.1 U.S.
      • 5.2.4.1.1 Country Overview
      • 5.2.4.1.2 Driving Factors for Market Growth
      • 5.2.4.1.3 Factors Challenging the Market
      • 5.2.4.1.4 Market Sizing and Forecast
    • 5.2.4.2 Canada
      • 5.2.4.2.1 Country Overview
      • 5.2.4.2.2 Driving Factors for Market Growth
      • 5.2.4.2.3 Factors Challenging the Market
      • 5.2.4.2.4 Market Sizing and Forecast
• 5.3 Europe
  • 5.3.1 Regional Overview
  • 5.3.2 Driving Factors for Market Growth
  • 5.3.3 Factors Challenging the Market
  • 5.3.4 Market Sizing and Forecast
    • 5.3.4.1 U.K.
      • 5.3.4.1.1 Country Overview
      • 5.3.4.1.2 Driving Factors for Market Growth
      • 5.3.4.1.3 Factors Challenging the Market
      • 5.3.4.1.4 Market Sizing and Forecast
    • 5.3.4.2 Germany
      • 5.3.4.2.1 Country Overview
      • 5.3.4.2.2 Driving Factors for Market Growth
      • 5.3.4.2.3 Factors Challenging the Market
      • 5.3.4.2.4 Market Sizing and Forecast
    • 5.3.4.3 France
      • 5.3.4.3.1 Country Overview
      • 5.3.4.3.2 Driving Factors for Market Growth
      • 5.3.4.3.3 Factors Challenging the Market
      • 5.3.4.3.4 Market Sizing and Forecast
    • 5.3.4.4 Italy
      • 5.3.4.4.1 Country Overview
      • 5.3.4.4.2 Driving Factors for Market Growth
      • 5.3.4.4.3 Factors Challenging the Market
      • 5.3.4.4.4 Market Sizing and Forecast
    • 5.3.4.5 Spain
      • 5.3.4.5.1 Country Overview
      • 5.3.4.5.2 Driving Factors for Market Growth
      • 5.3.4.5.3 Factors Challenging the Market
      • 5.3.4.5.4 Market Sizing and Forecast
    • 5.3.4.6 Rest-of-the- Europe
      • 5.3.4.6.1 Country Overview
      • 5.3.4.6.2 Driving Factors for Market Growth
      • 5.3.4.6.3 Factors Challenging the Market
      • 5.3.4.6.4 Market Sizing and Forecast
• 5.4 Asia Pacific
  • 5.4.1 Regional Overview
  • 5.4.2 Driving Factors for Market Growth
  • 5.4.3 Factors Challenging the Market
  • 5.4.4 Market Sizing and Forecast
    • 5.4.4.1 China
      • 5.4.4.1.1 Country Overview
      • 5.4.4.1.2 Driving Factors for Market Growth
      • 5.4.4.1.3 Factors Challenging the Market
      • 5.4.4.1.4 Market Sizing and Forecast
    • 5.4.4.2 Japan
      • 5.4.4.2.1 Country Overview
      • 5.4.4.2.2 Driving Factors for Market Growth
      • 5.4.4.2.3 Factors Challenging the Market
      • 5.4.4.2.4 Market Sizing and Forecast
    • 5.4.4.3 India
      • 5.4.4.3.1 Country Overview
      • 5.4.4.3.2 Driving Factors for Market Growth
      • 5.4.4.3.3 Factors Challenging the Market
      • 5.4.4.3.4 Market Sizing and Forecast
    • 5.4.4.4 Australia
      • 5.4.4.4.1 Country Overview
      • 5.4.4.4.2 Driving Factors for Market Growth
      • 5.4.4.4.3 Factors Challenging the Market
      • 5.4.4.4.4 Market Sizing and Forecast
    • 5.4.4.5 South Korea
      • 5.4.4.5.1 Country Overview
      • 5.4.4.5.2 Driving Factors for Market Growth
      • 5.4.4.5.3 Factors Challenging the Market
      • 5.4.4.5.4 Market Sizing and Forecast
    • 5.4.4.6 Rest-of-the-Asia Pacific
      • 5.4.4.6.1 Country Overview
      • 5.4.4.6.2 Driving Factors for Market Growth
      • 5.4.4.6.3 Factors Challenging the Market
      • 5.4.4.6.4 Market Sizing and Forecast
• 5.5 Rest-of-the-World
  • 5.5.1 Regional Overview
  • 5.5.2 Driving Factors for Market Growth
  • 5.5.3 Factors Challenging the Market
  • 5.5.4 Market Sizing and Forecast

6 Competitive Benchmarking and Company Profiles

• 6.1 Global Breast Cancer Screening and Diagnostics Market, Key Strategies and Developments, January 2023-April 2026
• 6.2 Key Developments Analysis (by Company), January 2023-June 2026
• 6.3 Company Profiles
  • 6.3.1 Becton, Dickinson and Company
    • 6.3.1.1 Overview
    • 6.3.1.2 Top Products
    • 6.3.1.3 Top Competitors
    • 6.3.1.4 Key Personnel
    • 6.3.1.5 Analyst View
  • 6.3.2 Canon
    • 6.3.2.1 Overview
    • 6.3.2.2 Top Products
    • 6.3.2.3 Top Competitors
    • 6.3.2.4 Key Personnel
    • 6.3.2.5 Analyst View
  • 6.3.3 F. Hoffmann-La Roche Ltd
    • 6.3.3.1 Overview
    • 6.3.3.2 Top Products
    • 6.3.3.3 Top Competitors
    • 6.3.3.4 Key Personnel
    • 6.3.3.5 Analyst View
  • 6.3.4 FUJIFILM Corporation
    • 6.3.4.1 Overview
    • 6.3.4.2 Top Products
    • 6.3.4.3 Top Competitors
    • 6.3.4.4 Key Personnel
    • 6.3.4.5 Analyst View
  • 6.3.5 GE Healthcare
    • 6.3.5.1 Overview
    • 6.3.5.2 Top Products
    • 6.3.5.3 Top Competitors
    • 6.3.5.4 Key Personnel
    • 6.3.5.5 Analyst View
  • 6.3.6 Hologic, Inc.
    • 6.3.6.1 Overview
    • 6.3.6.2 Top Products
    • 6.3.6.3 Top Competitors
    • 6.3.6.4 Key Personnel
    • 6.3.6.5 Analyst View
  • 6.3.7 Koninklijke Philips N.V.
    • 6.3.7.1 Overview
    • 6.3.7.2 Top Products
    • 6.3.7.3 Top Competitors
    • 6.3.7.4 Key Personnel
    • 6.3.7.5 Analyst View
  • 6.3.8 Seno Medical
    • 6.3.8.1 Overview
    • 6.3.8.2 Top Products
    • 6.3.8.3 Top Competitors
    • 6.3.8.4 Key Personnel
    • 6.3.8.5 Analyst View
  • 6.3.9 Siemens Healthineers
    • 6.3.9.1 Overview
    • 6.3.9.2 Top Products
    • 6.3.9.3 Top Competitors
    • 6.3.9.4 Key Personnel
    • 6.3.9.5 Analyst View
  • 6.3.10 Planmed Oy
    • 6.3.10.1 Overview
    • 6.3.10.2 Top Products
    • 6.3.10.3 Top Competitors
    • 6.3.10.4 Key Personnel
    • 6.3.10.5 Analyst View
  • 6.3.11 QIAGEN
    • 6.3.11.1 Overview
    • 6.3.11.2 Top Products
    • 6.3.11.3 Top Competitors
    • 6.3.11.4 Key Personnel
    • 6.3.11.5 Analyst View

7 Research Methodology

• 7.1 Data Sources
  • 7.1.1 Primary Data Sources
  • 7.1.2 Secondary Data Sources
  • 7.1.3 Data Triangulation
• 7.2 Market Estimation and Forecast